



20 April 2026

cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

AGM – supplementary disclosure

Cyclopharm Limited (**ASX:CYC**) refers to its Notice of Annual General Meeting and Explanatory Memorandum which was dispatched on 10 April 2026 (**Notice of Meeting**).

After the Notice of Meeting was dispatched, the Company received \$5 million of subscription monies for Tranche 2 of the Placement announced on 4 February 2026 in anticipation of settlement on 20 April 2026.

On 14 April 2026, the Company received confirmation that the shares will be allocated to Barings Acceptance Limited, who currently own 12,022,415 fully-paid ordinary shares (or 9.95% of issued capital).

Accordingly, the Company updates its disclosure regarding investor participation in Tranche 2 and advises that Barings Acceptance Limited is the only participant in Tranche 2 of the Placement and is a substantial holder in the Company but is not an associate of:

- a Related Party of the Company;
- a member of the Company's key management personnel;
- any other substantial holder in the Company; or
- an adviser to the Company.

Other than as set out in this announcement, all details in the Notice of Meeting remain unchanged. There is no change to the Proxy Form provided with the Notice of Meeting and Proxy Forms already submitted remain valid for all Resolutions (unless changed by the lodgment of a further Proxy Form).

A copy of this announcement will be made available to shareholders at the link provided in the access letter for the Notice of Meeting.

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

For personal use only